News

Modern Healthcare17d
Eli Lilly denies affiliation with Hims & Hers
Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug.
Stocktwits on MSN17d
Hims & Hers Adds Eli Lilly's Zepbound To Weight-Loss Offerings: Retail Excited Despite BofA Seeing 'Immaterial' Sales Impact
Shares of Hims & Hers Health Inc. ended Tuesday over 5% higher, lifting retail investor mood after the telehealth company announced it was adding two new weight-loss medications to its platform.
Seeking Alpha15d
Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner
Eli Lilly and Company is the world's most valuable Pharma thanks to tirzepatide, a groundbreaking GLP-1 weight-loss and Type 2 Diabetes drug, marketed and sold as Zepbound / Mounjaro. Hims & ...
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...
HIMS Stock: Time For A Turnaround?
HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...
Patients Cut Off From Cheaper Obesity Drugs as the F.D.A. Halts Sales of Copycats
U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...